Prothena_RGB_fullcolor.jpg
Prothena Reports First Quarter Financial Results
14 mai 2013 16h05 HE | Prothena Corporation plc
DUBLIN, Ireland, May 14, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the...
Prothena_RGB_fullcolor.jpg
First Patient Dosed in Phase I Study of Prothena's Therapeutic Antibody for Treatment of AL Amyloidosis
23 avr. 2013 16h05 HE | Prothena Corporation plc
DUBLIN, Ireland, April 23, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the...
Prothena_RGB_fullcolor.jpg
Prothena Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Research and Development Update
28 mars 2013 16h05 HE | Prothena Corporation plc
Company Advances Pipeline With Strong Capital Position Following 2012 Spin-Off NEOD001 to Enter Clinic in Early 2013 DUBLIN, Ireland, March 28, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc...
Prothena_RGB_fullcolor.jpg
Prothena Announces Appointments of Chief Medical Officer and Chief Financial Officer
25 mars 2013 16h30 HE | Prothena Corporation plc
DUBLIN, Ireland, March 25, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential...
Prothena_RGB_fullcolor.jpg
Prothena to Report Fourth Quarter and Full Year 2012 Financial Results and Host Webcast and Conference Call on March 28, 2013
21 mars 2013 16h05 HE | Prothena Corporation plc
DUBLIN, Ireland, March 21, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential...
Prothena_RGB_fullcolor.jpg
Prothena Achieves Orphan Drug Status in EU for Lead Program NEOD001
27 févr. 2013 16h30 HE | Prothena Corporation plc
DUBLIN, Ireland, Feb. 27, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential...
Prothena_RGB_fullcolor.jpg
Prothena to Ring NASDAQ Stock Market Opening Bell
13 févr. 2013 06h00 HE | Prothena Corporation plc
DUBLIN, Ireland, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential...
Prothena_RGB_fullcolor.jpg
Prothena Announces Addition of Industry Veterans to Board of Directors
07 janv. 2013 08h00 HE | Prothena Corporation plc
DUBLIN, Ireland, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential...
Prothena_RGB_fullcolor.jpg
Prothena Begins Trading on NASDAQ Global Market Under Symbol "PRTA"
21 déc. 2012 01h30 HE | Prothena Corporation plc
DUBLIN, Ireland, Dec. 21, 2012 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential...